Stanford spinout raises $14 million for its point-of-care physician consulting service

0

There is a serious evidence gap in health care treatment guidelines. Clinical trials inform most care policies and payer decisions, but exclude about 70% of the US population, according to Brigham Hyde, co-founder and CEO of Atropo’s health. He pointed out that these dynamics are even more pronounced in patients with chronic comorbidities or those belonging to rare groups, such as children or people with rare diseases.

The Hyde startup got closer to its mission to fill that evidence gap last week when it announced the closing of a $14 million Series A funding round. Breyer Capital led the round with participation from Emerson Collective and Boston Millennia Partners.

Atropos Health provides physicians with real-world evidence at the point of care to help them make more informed decisions about the care of their patients. The idea for the company came from Nigam Shah, a professor of biomedical informatics at Stanford University.

Stanford Healthcare Doctors used to regularly send inquiries to Shah, asking him to glean insights from EMR data and answer their questions about how best to treat patients. So he built what he called “the Green Button Service,” a tool that analyzed Stanford’s EMR data and provided a consultation report to the doctors. Shah led the service at Stanford for about 18 months before the university approached Hyde – who was most recently an executive at a life sciences company Eversana – to help spin it off as a new company in 2020.

Shah and Hyde — along with their other co-founder, Saurabh Gombar, a Stanford researcher and physician — founded Atropos Health with the goal that one day physicians would have to do less extrapolation. Rather than often relying on educated guesses, they wanted doctors to have quick access to evidence about which treatments work for specific patients.

Atropos’ technology produces a report called a prognostogram, which Hyde describes as a “complete, publication-ready observational research study of deidentified EMR patients, including the use of high-dimensional propensity score matching for statistical error correction.” Doctors make these predictions at the point of care, which is important because they often have patients in their offices with follow-ups scheduled in a day or two.

Speed ​​and ease of use are the top priorities for the developers at Atropos. As for the company, the company only asks doctors for a few sentences about their patient’s situation, similar to an email they send to a colleague.

The startup charges its customers for a platform subscription and installs its technology on their EMR records. The startup also charges fees for its forecasts, which can be based on a volume or employee basis. However, the services are reimbursable – Hyde said doctors can be reimbursed for ordering reports and atropos can be paid deliver.

Atropos currently sells its services to academic medical centers. Half a dozen institutions use them, and the company serves about 10,000 doctors, according to Hyde.

Commissioning in May signed a partnership With ASCO CancerLinQ, which collects EMR data from oncology practices across the country. The partnership not only gives Atropos access to ASCO’s wealth of oncology data to help the company answer specific questions about cancer care, but also access to all CancerLinQ memberships. Hyde said this means more than 150 local oncology practices can now order prognostograms.

Atropos will use a portion of the funds raised from its Series A funding to advance the oncology consulting product it is developing with ASCO. It will also use the money to expand its commercial team.

As the startup continues to grow, Hyde is focused on building a service that not only helps doctors make better decisions, but also leads to better patient outcomes. He said this mission speaks for the startup’s name – Atropos is one of the three Moirai in Greek mythology, goddesses who assigned people their destiny. He said the company’s main goal is to create a sunnier destiny for patients.

Photo: 3283197d_273, Getty Images

Share.

Comments are closed.